Biohaven Pharmaceutical Holding has patented a pharmaceutical composition containing substituted riluzole prodrugs for treating various cancers. The prodrugs are stable to hepatic metabolism, released in the plasma via enzymatic or biophysical processes, and administered orally for enhanced delivery. GlobalData’s report on Biohaven Pharmaceutical Holding gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biohaven Pharmaceutical Holding, was a key innovation area identified from patents. Biohaven Pharmaceutical Holding's grant share as of February 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for cancer treatment with riluzole prodrugs
A recently granted patent (Publication Number: US11911369B2) discloses a pharmaceutical composition comprising a compound with a specific chemical formula (I). The composition includes various compounds selected from a group that includes 2-(methylamino)-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino) ethyl)acetamide, 2-(ethylamino)-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino) ethyl)acetamide, and others, or their pharmaceutically acceptable forms.
Moreover, the patent claims cover the pharmaceutical composition in different forms such as tablets, orally dissolving tablets, and capsules. The orally dissolving tablet variations may contain gelatin or mannitol, while the capsules may include binders, disintegrants, glidants, or lubricants like mannitol, microcrystalline cellulose, colloidal silicon dioxide, or magnesium stearate. These specific formulations and compositions are protected under the granted patent, ensuring exclusivity for the inventors in utilizing these specific combinations for pharmaceutical purposes.
To know more about GlobalData’s detailed insights on Biohaven Pharmaceutical Holding, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
